Obermatt
See Similar Stocks →

Sol-Gel Technologies

NAQ:SLGL · IL0011417206
PharmaceuticalsX-Small

360

36
Medium confidence — indicative
Profit price—
Cash yield1
Price/Sales7
EV / Gross Profit3
Price/Book1
Return on Capital41
Return on Equity50
EBIT Margin20
Gross Profitability13

Cash truth not applicable for financial companies.

Sales growth1
Profit growth19
Reinvestment4
Price momentum100
Debt load87
Debt serviceability25
Liquidity1
Analyst ratings100
Opinion Changes100
Price Target Upside56
Market mood5
Value Creation10/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Sol-Gel Technologies clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Based on 3/5 components.

Profile

CountryIsrael
IndustryPharmaceuticals
SizeX-Small
TypePublic Company
ExchangeNASDAQCM
Founded1997
Employees38
Websitesol-gel.com
ISINIL0011417206
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
DermatologyGenetic DisorderBiotechnologyPharmaceutical

Description

Sol-Gel Technologies Ltd. operates as a dermatology company. The company leverages innovative approaches to develop treatments for patients with severe skin conditions, with a track record of two New Drug Application (NDA) approvals and a pipeline o…

Analysis

Middle-of-the-road

Sol-Gel Technologies Ltd. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is stretched. The company scores 10/20 on our value-creation score: creating some value. Analysts lean positive.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
15
2023202420252026

All-time high

63

Jan 2025

All-time low

1

Jan 2024

Average rank

27

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
7
38
3
13
Price/Earnings
93
26
26
25
Price/Book
1
91
84
27
Dividend Yield
1
1
1
1
Value (overall)
17
37
27
10

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Sol-Gel Technologies with its peers
Novartis
VTX:NOVN
38
CountrySwitzerland
IndustryPharmaceuticals
SizeXX-Large
Full Stock Analysis →
Hikma Pharmaceuticals
LSE:HIK
47
CountryUK
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
DiaSorin
MIL:DIA
34
CountryItaly
IndustryHealth Care Equipment & Supplies
SizeLarge
Full Stock Analysis →
Cosmo Pharmaceuticals
SWX:COPN
47
CountryIreland
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Almirall
MCE:ALM
74
CountrySpain
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Curatis Holding
SWX:CURN
70
CountrySwitzerland
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →